OCUL
Ocular Therapeutix, Inc. Healthcare - Biotechnology Investor Relations →
Ocular Therapeutix, Inc. (OCUL) closed at $8.18 as of 2026-03-20, trading 16.8% above its 200-week moving average of $7.01. The stock is currently moving closer to the line, down from 25.5% last week. With a 14-week RSI of 22, OCUL is in oversold territory.
Over the past 14 weeks, up-weeks have carried more volume than down-weeks (1.69 buyers-vs-sellers ratio). When trading picks up, it's more often on days the price is rising — buyers are showing more interest than sellers.
Over the past 560 weeks of data, OCUL has crossed below its 200-week moving average 5 times. On average, these episodes lasted 77 weeks. The average one-year return after crossing below was -19.7%, suggesting these dips have not historically been reliable buying opportunities for this stock.
With a market cap of $1781 million, OCUL is a small-cap stock. Free cash flow yield is currently negative, meaning the company is burning cash. Return on equity stands at -54.9%. The stock trades at 2.7x book value.
Share count has increased 179.7% over three years, indicating dilution.
Over the past 10.8 years, a hypothetical investment of $100 in OCUL would have grown to $41, compared to $379 for the S&P 500. OCUL has returned -8.0% annualized vs 13.1% for the index, underperforming the broader market over this period.
Free cash flow has been declining. A deteriorating cash flow trend warrants extra scrutiny — the stock may be cheap for a reason.
Business Health
Annual financials — how the underlying business has performed over the past several years.
Cash Flow Free cash flow & net income ($M)
Revenue Annual revenue ($M) — business growth proxy
Total Debt Balance sheet debt ($M)
ROIC Return on invested capital (%)
FCF Yield Free cash flow / market cap (%) — Yartseva signal
Gross Margin Pricing power & competitive moat (%)
Shares Outstanding Buybacks vs dilution (millions)
Growth of $100: OCUL vs S&P 500
Monthly data normalized to $100 at start. Vertical dashed lines mark 200-week MA touches.
What Happens After OCUL Crosses Below the Line?
Across 5 historical episodes, buying OCUL when it crossed below its 200-week moving average produced an average return of -18.0% after 12 months (median -47.0%), compared to +5.8% for the S&P 500 over the same periods. 40% of those episodes were profitable after one year. After 24 months, the average return was -55.7% vs +15.7% for the index.
Each line shows $100 invested at the moment OCUL crossed below its 200-week MA. Bold blue = stock average. Gray dashed = S&P 500 average over same periods.
Historical Touches
OCUL has crossed below its 200-week MA 5 times with an average 1-year return of +-19.7% after recovery.
| Crossed Below | Recovered | Weeks | Max Depth | 1-Year Return | Return Since Touch |
|---|---|---|---|---|---|
| Jun 2015 | Jul 2015 | 2 | 11.3% | -75.7% | -59.4% |
| Aug 2015 | May 2020 | 248 | 73.9% | -69.5% | -61.5% |
| Oct 2021 | Feb 2024 | 122 | 73.4% | -46.7% | +18.4% |
| Apr 2024 | Jul 2024 | 12 | 40.2% | +40.0% | +56.7% |
| Jul 2024 | Aug 2024 | 1 | 0.5% | +53.2% | +5.1% |
| Average | 77 | — | +-19.7% | — |
Frequently Asked Questions
Is OCUL below its 200-week moving average?
No. Ocular Therapeutix, Inc. (OCUL) is currently 16.8% above its 200-week moving average of $7.01. It would need to fall to $7.01 to cross below the line.
What is OCUL's 200-week moving average price?
Ocular Therapeutix, Inc.'s 200-week moving average is $7.01 as of 2026-03-20. This is the average weekly closing price over roughly the last 4 years, and it acts as a long-term trend line. When a stock drops below this level, it can signal that the price has fallen far enough from the long-term trend to attract value-oriented investors.
What happens when OCUL drops below its 200-week moving average?
OCUL has crossed below its 200-week moving average 5 times in our data. The average one-year return after these crossings was -19.7%, meaning the dips were not reliable buying signals for this particular stock. These episodes lasted 77 weeks on average.
Is OCUL a good value right now?
Here's what our data says about OCUL as of 2026-03-20: The stock is above its 200-week moving average, so it doesn't currently meet our primary signal. The 14-week RSI is 22 (oversold). Free cash flow is currently negative. Return on equity is -54.9%. Price-to-book is 2.7x. This is not a buy or sell recommendation — always do your own research.
How does OCUL compare to the S&P 500?
Over the past 10.8 years, $100 invested in OCUL would have grown to $41, compared to $379 for the S&P 500. That's -8.0% annualized vs 13.1% for the index. OCUL has underperformed the broader market over this period.
Not financial advice. This is an educational tool. Past performance does not guarantee future results. Do your own research before making investment decisions.
Data as of week of 2026-03-20